Horizon enrolls first subject in Phase II trial of antibody for DLE treatment

Horizon Therapeutics has announced the enrolment of the first patient in a Phase II clinical trial of its antibody daxdilimab for treating discoid lupus erythematosus (DLE).

The placebo-controlled, randomised trial has been designed to assess the company’s development-stage medicine daxdilimab for individuals with moderate-to-severe primary DLE, a rare, chronic, inflammatory skin condition.